ClinicalTrials.gg
CompletedNCT00502853Updated Aug 16, 2017Results posted

A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.

A Phase 4 interventional study of rituximab [MabThera/Rituxan] and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-16.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
59th of 63
10 · median 159
Started
2007
with 10 others
Phase 4
14 of 63
3 open now
Registered
15th of 63
by date
Lead sponsor
20 of 63
Hoffmann-La Roche

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 59th largest by enrollment, is one of 11 that started in 2007, is one of 14 in phase 4, and was the 15th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This single arm study will measure the effect of MabThera in combination with methotrexate on the progression of synovitis, the extent of bone marrow edema, and the number of erosions in the wrist and hand of patients with rheumatoid arthritis, using a new MRI technique. Patients will receive MabThera 1000mg i.v. on days 1 and 15, in combination with a stable dosage of 10-25mg/week methotrexate throughout the duration of the study. Further courses of MabThera will be provided to eligible patients. MRI will be performed 1-2 weeks before treatment initiation, and repeated 1 and 6 months after the first MabThera infusion. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-75 years of age;
  • rheumatoid arthritis for >=3 months and \<=10 years;
  • inadequate response to methotrexate (12.5-25mg/week) for >=3 months;
  • evidence of erosive disease and/or clinical synovitis in a signal joint.

Exclusion criteria

Exclusion Criteria:

  • rheumatic diseases other than RA;
  • surgical operations on bones/joints in 12 weeks prior to baseline visit;
  • concomitant treatment with biologic agents;
  • previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [MabThera/Rituxan] · Drug: Methotrexate

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000mg iv on days 1 and 15

  • 10-25mg/week

06

What researchers measure

Primary outcomes

  1. Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score

    Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT. Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium. Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint. 1st carpometacarpal joint and 1st MCP joint are not scored. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score=the sum of the individual scores (3 wrist regions \[range 0-9\] or 4 MCP joints \[range 0-12\]) for an overall range of 0-21, where 0=no damage and maximum score \[9, 12, or 21\]=most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.

    Time frame: Baseline, Week 4, and Week 24

  2. OMERACT RAMRIS Bone Edema Score

    Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT. Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous. Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema. Change in bone edema = follow-up bone edema score - baseline score.

    Time frame: Baseline, Weeks 4 and 24

  3. OMERACT RAMRIS Erosion Score

    MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately. Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc). For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone. Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion. Change in erosion=Follow-up erosion score - baseline score.

    Time frame: Baseline, Week 4, and Week 24

  4. Early Enhancement Rate (REE)

    A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI, i.e. Contrast-Enhanced Dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its "steady state" condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%. The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher.

    Time frame: Baseline, Weeks 4 and 24

  5. Relative Enhancement (RE) Score

    A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (REE) and its "steady state" condition (RE).

    Time frame: Baseline, Weeks 4 and 24

Secondary outcomes

  1. Ritchie Articular Index Scores

    The Ritchie Articular Index is a graded assessment of tenderness in 26 joint regions. The sum of the grades of tenderness (0=not tender, 1=tender, 2=tender and causes wince, and 3 tender, causes wince and effort to withdraw) elicited by applying firm pressure over the joint margin of articular joints (such as shoulders, elbow, wrists, hips). The scores ranged from 0 (no tenderness) to 78 (most severe tenderness).

    Time frame: Baseline and Weeks 4, 12, and 24

  2. Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis (RA). It consist of 20 items referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item within a domain was scored on a 4-point Likert scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. The highest score reported by the participant for a domain determined the score for that domain. The overall disability index is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline and Weeks 4, 12, and 24

  3. Patient's Global Assessment of Pain

    The participant's assessment of their current level of pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line was described as "no pain" and the right-hand as "unbearable pain". The participant was asked to mark the line corresponding to their current level of pain and the distance from the left edge was recorded.

    Time frame: Baseline and Weeks 4, 12, and 24

  4. DAS28 Score

    DAS28 calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A DAS28 score of less than or equal to (≤) 3.2 = low disease activity, a DAS28 score of \>3.2 to 5.1 = moderate to high disease activity.

    Time frame: Baseline and Weeks 4, 12, and 24

  5. Erythrocyte Sedimentation Rate (ESR)

    ESR was determined using the Westergren method. ESR measures how fast red blood cells (erythrocytes) fall to the bottom of a fine glass tube that is filled with the participant's blood. The higher the sedimentation rate the greater the inflammation.

    Time frame: Baseline and Weeks 4, 12, and 24

  6. C-Reactive Protein (CRP)

    CRP measured by milligrams per deciliter (mg/dL). High levels of CRP are indicators of active inflammation.

    Time frame: Baseline and Weeks 4, 12, and 24

  7. Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count

    Anti-CCP autoantibodies count measured by units per milliliter (U/mL). The anti-CCP autoantibodies bind antigenic determinants that contain the unusual amino acid citrulline. The anti-CCP antibody is a highly specific diagnostic test of RA (though with variable sensitivity) and a marker of joint damage with high prognostic significance.

    Time frame: Baseline and Weeks 4, 12, and 24

  8. Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations

    RF IgM concentrations measured by international units per milliliter (IU/mL). RF is an antibody reacting against the fragment, crystallizable (Fc) region of IgG. Quantitative measurements have shown a prognostic value in distinguishing between progressive and non-progressive disease in early RA, a correlation with radiologically determined joint damage, and relation with clinical improvement after disease-modifying anti-rheumatic treatment.

    Time frame: Baseline and Weeks 4, 12, and 24

  9. Total Immunoglobulin (Ig) Concentrations

    Total Ig concentrations as measured by milligrams per milliliter (mg/mL).

    Time frame: Baseline and Weeks 4, 12, and 24

  10. Hematocrit Concentration (%)

    Time frame: Baseline and Weeks 4, 12, and 24

  11. Percentage of Total B-lymphocytes

    Concentration of all B-lymphocytes subtypes was assessed.

    Time frame: Baseline and Weeks 4, 12, and 24

  12. Erosion Score - Right Hand

    The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.

    Time frame: Baseline and Week 24

  13. Erosion Score - Left Hand

    The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.

    Time frame: Baseline and Week 24

  14. Joint Space Narrowing - Right Hand

    Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 times \[x\] 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).

    Time frame: Baseline and Week 24

  15. Joint Space Narrowing - Left Hand

    Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 x 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).

    Time frame: Baseline and Week 24

  16. X-Rays: Right Hand Total Score

    Right hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and scores ranged from 0 (best possible outcome) to 180 (worst possible outcome).

    Time frame: Baseline and Week 24

  17. X-Rays: Left Hand Total Score

    Left hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and ranged from 0 (best possible outcome) to 180 (worst possible outcome).

    Time frame: Baseline and Week 24

07

Results

Posted Mar 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneRituximab Plus (+) Methotrexate (MTX)
Started10
Completed10
Not completed0

Outcome measures

PrimaryOutcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score

Extension and degree of synovitis in wrist according to RAMRIS score developed by OMERACT. Synovitis is an area in synovial compartment that shows above normal post-gadolinium enhancement of a thickness greater than width of normal synovium. Synovitis is assessed in 3 wrist regions (distal radioulnar joint; radiocarpal joint; intercarpal and carpometacarpal joints) and in each metacarpophalangeal (MCP) joint. 1st carpometacarpal joint and 1st MCP joint are not scored. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Total synovitis score=the sum of the individual scores (3 wrist regions \[range 0-9\] or 4 MCP joints \[range 0-12\]) for an overall range of 0-21, where 0=no damage and maximum score \[9, 12, or 21\]=most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.

Time frame:
Baseline, Week 4, and Week 24
Reported as:
Mean · units on a scale
Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score
units on a scaleRituximab + MTX
Baseline3.4 ± 1.58
Week 42.3 ± 2.75
Change at Week 4-1.1 ± 2.38
Week 242.4 ± 1.74
Change at Week 24-1.0 ± 1.73
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.1776
  • Rituximab + MTX · Student's t-test · p = 0.1215
  • Rituximab + MTX · Random coefficient model · p = 0.2246 · Slope: -0.1606
PrimaryOMERACT RAMRIS Bone Edema Score

Extension and degree of bone edema in the wrist according to the RAMRIS score developed by OMERACT. Bone edema is a lesion within the trabecular bone, with ill-defined margins and signal characteristics consistent with increased water content. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale of 0-3 was based on the proportion of bone with edema, as follows: 0=no edema; 1=1 percent (%) to 33% of bone was edematous; 2 = 34%-66% of bone was edematous; and 3= 67%-100% of bone was edematous. Total bone edema score=sum of the individual scores for an overall range of 0-69, where 0=no edema and 69=most severe edema. Change in bone edema = follow-up bone edema score - baseline score.

Time frame:
Baseline, Weeks 4 and 24
Reported as:
Mean · units on a scale
OMERACT RAMRIS Bone Edema Score
units on a scaleRituximab + MTX
Baseline23.2 ± 13.56
Week 423.8 ± 15.68
Change at Week 40.6 ± 14.52
Week 2424.0 ± 14.66
Change at Week 240.8 ± 16.77
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.8989
  • Rituximab + MTX · Student's t-test · p = 0.8834
  • Rituximab + MTX · Random coefficient model · p = 0.8841 · Slope: 0.1357
PrimaryOMERACT RAMRIS Erosion Score

MRI bone erosion measures a sharply marginated bone lesion, with correct juxta-articular localization and typical signal characteristics, which is visible in 2 planes with a cortical break seen in at least 1 plane. Each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) scored separately. Scale is 0-10 based on proportion of eroded bone compared to assessed bone volume (0=no erosion; 1=1%-10% of bone eroded; 2=11%-20%, etc). For long bones, assessed bone volume is from articular surface (or best estimated position if absent) to depth of 1 centimeter (cm); in carpal bones it is the whole bone. Total erosion score=sum of individual scores for an overall range of 0-230, where 0=no erosion and 230=most severe erosion. Change in erosion=Follow-up erosion score - baseline score.

Time frame:
Baseline, Week 4, and Week 24
Reported as:
Mean · units on a scale
OMERACT RAMRIS Erosion Score
units on a scaleRituximab + MTX
Baseline7.9 ± 3.67
Week 48.1 ± 3.63
Change at Week 40.2 ± 1.14
Week 249.1 ± 4.38
Change at Week 241.2 ± 2.39
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.5911
  • Rituximab + MTX · Student's t-test · p = 0.1475
  • Rituximab + MTX · Random coefficient model · p = 0.1463 · Slope: 0.1786
SecondaryRitchie Articular Index Scores

The Ritchie Articular Index is a graded assessment of tenderness in 26 joint regions. The sum of the grades of tenderness (0=not tender, 1=tender, 2=tender and causes wince, and 3 tender, causes wince and effort to withdraw) elicited by applying firm pressure over the joint margin of articular joints (such as shoulders, elbow, wrists, hips). The scores ranged from 0 (no tenderness) to 78 (most severe tenderness).

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · units on a scale
Ritchie Articular Index Scores
units on a scaleRituximab + MTX
Baseline20.7 ± 8.30
Week 416.9 ± 9.49
Change at Week 4-3.8 ± 6.78
Week 129.5 ± 6.72
Change at Week 12-11.2 ± 6.11
Week 2411.7 ± 9.60
Change at Week 24-9.0 ± 6.50
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.1101
  • Rituximab + MTX · Student's t-test · p = 0.0003
  • Rituximab + MTX · Student's t-test · p = 0.0018
  • Rituximab + MTX · Random coefficient model · p = 0.0023 · Slope: -2.0857
PrimaryEarly Enhancement Rate (REE)

A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI, i.e. Contrast-Enhanced Dynamic MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (rate of early enhancement - REE) and its "steady state" condition (relative enhancement - RE). REE per second during the first 55 seconds was calculated according to the formula REE55 = (S55-S0)/(S0x55)x100%. The REE shows the slope of the curve of contrast uptake tangential to the α angle and is steeper if inflammation is higher.

Time frame:
Baseline, Weeks 4 and 24
Reported as:
Mean · percent per second
Early Enhancement Rate (REE)
percent per secondRituximab + MTX
Baseline0.356 ± 0.2651
Week 40.489 ± 0.5110
Change at Week 40.150 ± 0.4106
Week 240.363 ± 0.2615
Change at Week 24-0.012 ± 0.3227
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.3358
  • Rituximab + MTX · Student's t-test · p = 0.9158
  • Rituximab + MTX · Random coefficient model · p = 0.8877 · Slope: 0.003418
PrimaryRelative Enhancement (RE) Score

A low cost, low field dedicated extremity MRI unit was used, which is specifically designed for the examination of peripheral joints. In addition to the standard OMERACT-RAMRIS scoring system, additional data were elaborated by using "dynamic" MRI (DCE-MRI). This method evaluates the diffusion of the contrast mean in a series of very short sequences thus providing a diffusion curve which is proportionate to the extent of inflammation in the synovial membrane. Numerical parameters used with this method are the slope in the initial phase (REE) and its "steady state" condition (RE).

Time frame:
Baseline, Weeks 4 and 24
Reported as:
Mean · percent
Relative Enhancement (RE) Score
percentRituximab + MTX
Baseline66.978 ± 42.3981
Week 457.889 ± 51.9276
Change at Week 4-3.812 ± 34.3034
Week 2440.075 ± 21.6891
Change at Week 24-34.450 ± 32.9609
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.7624
  • Rituximab + MTX · Student's t-test · p = 0.0212
  • Rituximab + MTX · Random coefficient model · p = 0.0712 · Slope: -4.2681
SecondaryHealth Assessment Questionnaire - Disability Index (HAQ-DI) Score

The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis (RA). It consist of 20 items referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item within a domain was scored on a 4-point Likert scale from 0 to 3: 0 = no difficulty; 1 = some difficulty; 2 = much difficulty; 3 = unable to do. The highest score reported by the participant for a domain determined the score for that domain. The overall disability index is computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · units on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
units on a scaleRituximab + MTX
Baseline1.788 ± 0.6848
Week 41.471 ± 0.7976
Change at Week 4-0.316 ± 0.3687
Week 120.838 ± 0.6668
Change at Week 12-0.950 ± 0.7997
Week 240.888 ± 0.7008
Change at Week 24-0.900 ± 0.6503
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.0240
  • Rituximab + MTX · Student's t-test · p = 0.0045
  • Rituximab + MTX · Student's t-test · p = 0.0018
  • Rituximab + MTX · Random Coefficient Model · p = 0.0019 · Slope: -0.1964
SecondaryPatient's Global Assessment of Pain

The participant's assessment of their current level of pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line was described as "no pain" and the right-hand as "unbearable pain". The participant was asked to mark the line corresponding to their current level of pain and the distance from the left edge was recorded.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · mm
Patient's Global Assessment of Pain
mmRituximab + MTX
Baseline60.6 ± 22.75
Week 449.0 ± 31.73
Change at Week 4-11.6 ± 20.38
Week 1234.7 ± 16.77
Change at Week 12-29.9 ± 28.27
Week 2422.7 ± 16.92
Change at Week 24-30.7 ± 23.69
Statistical analysis
  • Rituximab + MTX · Random Coefficient Model · p = 0.0074 · Slope: -6.6294
  • Rituximab + MTX · Student's t-test · p = 0.1273
  • Rituximab + MTX · Student's t-test · p = 0.0132
  • Rituximab + MTX · Student's t-test · p = 0.1542
SecondaryDAS28 Score

DAS28 calculated from the number of swollen joints and tender joints using the 28-joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \[mm/hr\]) and Patient's Global Assessment of Disease Activity (participant-rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. A DAS28 score of less than or equal to (≤) 3.2 = low disease activity, a DAS28 score of \>3.2 to 5.1 = moderate to high disease activity.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · units on a scale
DAS28 Score
units on a scaleRituximab + MTX
Baseline5.735 ± 0.8099
Week 45.261 ± 1.5552
Change at Week 4-0.474 ± 0.9250
Week 124.307 ± 1.4552
Change at Week 12-1.587 ± 0.9743
Week 244.400 ± 1.4263
Change at Week 24-1.335 ± 1.1425
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.1396
  • Rituximab + MTX · Student's t-test · p = 0.0050
  • Rituximab + MTX · Student's t-test · p = 0.0050
  • Rituximab + MTX · Random coefficient model · p = 0.0054 · Slope: -0.2902
SecondaryErythrocyte Sedimentation Rate (ESR)

ESR was determined using the Westergren method. ESR measures how fast red blood cells (erythrocytes) fall to the bottom of a fine glass tube that is filled with the participant's blood. The higher the sedimentation rate the greater the inflammation.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · mm/hr
Erythrocyte Sedimentation Rate (ESR)
mm/hrRituximab + MTX
Baseline72.6 ± 27.56
Week 463.8 ± 26.63
Change at Week 4-15.6 ± 15.61
Week 1248.0 ± 26.12
Change at Week 12-30.2 ± 26.47
Week 2453.4 ± 18.34
Change at Week 24-19.1 ± 21.25
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.0254
  • Rituximab + MTX · Student's t-test · p = 0.0384
  • Rituximab + MTX · Student's t-test · p = 0.0271
  • Rituximab + MTX · Random coefficient model · p = 0.0124 · Slope: -4.7586
SecondaryC-Reactive Protein (CRP)

CRP measured by milligrams per deciliter (mg/dL). High levels of CRP are indicators of active inflammation.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · mg/dL
C-Reactive Protein (CRP)
mg/dLRituximab + MTX
Baseline21.630 ± 24.1805
Week 423.480 ± 22.7518
Change at Week 41.850 ± 16.9261
Week 1210.929 ± 12.2432
Change at Week 12-10.929 ± 18.1919
Week 2423.410 ± 26.8998
Change at Week 241.780 ± 36.7504
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.7376
  • Rituximab + MTX · Student's t-test · p = 0.1631
  • Rituximab + MTX · Student's t-test · p = 0.8816
  • Rituximab + MTX · Random coefficient model · p = 0.8835 · Slope: -0.2927
SecondaryAnti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count

Anti-CCP autoantibodies count measured by units per milliliter (U/mL). The anti-CCP autoantibodies bind antigenic determinants that contain the unusual amino acid citrulline. The anti-CCP antibody is a highly specific diagnostic test of RA (though with variable sensitivity) and a marker of joint damage with high prognostic significance.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · U/mL
Anti-Cyclic Citrullinated Peptide (Anti-CCP) Autoantibodies Count
U/mLRituximab + MTX
Baseline55.230 ± 33.3902
Week 444.311 ± 28.4448
Change at Week 4-10.133 ± 18.0815
Week 1241.925 ± 32.2708
Change at Week 12-12.862 ± 16.7306
Week 24122.230 ± 247.7763
Change at Week 2467.000 ± 247.0019
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.1312
  • Rituximab + MTX · Student's t-test · p = 0.0662
  • Rituximab + MTX · Student's t-test · p = 0.4133
  • Rituximab + MTX · Random coefficient model · p = 0.6049 · Slope: 8.8196
SecondaryRheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations

RF IgM concentrations measured by international units per milliliter (IU/mL). RF is an antibody reacting against the fragment, crystallizable (Fc) region of IgG. Quantitative measurements have shown a prognostic value in distinguishing between progressive and non-progressive disease in early RA, a correlation with radiologically determined joint damage, and relation with clinical improvement after disease-modifying anti-rheumatic treatment.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · IU/mL
Rheumatoid Factor (RF) Immunoglobulin M (IgM) Concentrations
IU/mLRituximab + MTX
Baseline570.922 ± 827.0900
Week 4307.300 ± 337.9550
Change at Week 4-285.138 ± 530.8209
Week 12241.756 ± 357.8067
Change at Week 12-329.167 ± 499.0426
Week 24281.230 ± 337.6633
Change at Week 24-267.389 ± 529.7928
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.1725
  • Rituximab + MTX · Student's t-test · p = 0.0832
  • Rituximab + MTX · Student's t-test · p = 0.1685
  • Rituximab + MTX · Random coefficient model · p = 0.1331 · Slope: -55.4458
SecondaryTotal Immunoglobulin (Ig) Concentrations

Total Ig concentrations as measured by milligrams per milliliter (mg/mL).

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · mg/mL
Total Immunoglobulin (Ig) Concentrations
mg/mLRituximab + MTX
Baseline20.258 ± 6.7055
Week 417.786 ± 4.7033
Change at Week 4-1.602 ± 3.6846
Week 1217.296 ± 4.1845
Change at Week 12-2.336 ± 4.0998
Week 2418.354 ± 4.3432
Change at Week 24-1.042 ± 4.5527
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.2938
  • Rituximab + MTX · Student's t-test · p = 0.2216
  • Rituximab + MTX · Student's t-test · p = 0.5670
SecondaryHematocrit Concentration (%)
Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · percentage
Hematocrit Concentration (%)
percentageRituximab + MTX
Baseline36.110 ± 2.2218
Week 437.860 ± 1.4315
Change at Week 41.750 ± 2.9497
Week 1237.512 ± 2.5798
Change at Week 121.350 ± 4.3065
Week 2437.967 ± 2.6106
Change at Week 241.667 ± 3.6695
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.0934
  • Rituximab + MTX · Student's t-test · p = 0.4047
  • Rituximab + MTX · Student's t-test · p = 0.2101
  • Rituximab + MTX · Random coefficient model · p = 0.1451 · Slope: 0.3997
SecondaryPercentage of Total B-lymphocytes

Concentration of all B-lymphocytes subtypes was assessed.

Time frame:
Baseline and Weeks 4, 12, and 24
Reported as:
Mean · percentage of cells
Percentage of Total B-lymphocytes
percentage of cellsRituximab + MTX
Baseline24.040 ± 10.2954
Week 422.430 ± 8.0601
Change at Week 4-1.610 ± 7.1818
Week 1230.125 ± 12.0576
Change at Week 125.562 ± 11.6748
Week 2424.133 ± 10.2802
Change at Week 241.111 ± 7.7194
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.4963
  • Rituximab + MTX · Student's t-test · p = 0.2198
  • Rituximab + MTX · Student's t-test · p = 0.6773
  • Rituximab + MTX · Random coefficient model · p = 0.5531 · Slope: 0.3688
SecondaryErosion Score - Right Hand

The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Erosion Score - Right Hand
units on a scaleRituximab + MTX
Baseline2.50 ± 2.972
Week 242.19 ± 2.963
Change at Week 24-0.44 ± 1.741
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.5002
SecondaryErosion Score - Left Hand

The erosion score per joint of the hands can range from 0 to 5. Erosions were scored 1 if they were discrete but clearly present, and 2 or 3 if they were larger, depending on the surface area of the joint involved. A score of 3 was given if the erosion was large and extended over the imaginary middle of the bone. A score of 5 was given if a complete collapse of the joint was present or if the full surface of the joint was affected. In each joint, individual erosions were summed up to a maximum of 5. The maximal erosion score for each hand was thus 80, considering the 16 areas for erosions per hand.

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Erosion Score - Left Hand
units on a scaleRituximab + MTX
Baseline (n=10)1.90 ± 2.558
Week 24 (n=8)1.75 ± 2.619
Change at Week 24 (n=8)0.00 ± 0.707
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 1.0000
SecondaryJoint Space Narrowing - Right Hand

Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 times \[x\] 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Joint Space Narrowing - Right Hand
units on a scaleRituximab + MTX
Baseline10.40 ± 7.859
Week 2410.13 ± 6.786
Change at Week 240.94 ± 6.609
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.7002
SecondaryJoint Space Narrowing - Left Hand

Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4. A normal joint space was scored 0. A score of 2 was allowed to a focal narrowing of the joint or to a joint space not sufficiently narrowed to be scored 2. The score of 1 was not to be used when the reader was unsure whether there was joint space narrowing. A generalized narrowing leaving more than 50% of the original joint space present was scored 2. A generalized narrowing leaving less than 50% of the original joint space present was scored 3, and a subluxation of a joint was also scored 3. A bony ankylosis or a complete luxation of the joint was scored 4. A total of 13 joints were evaluated for narrowing and the scores were summed (13 x 4 \[maximum per joint\]). Each sum was normalized to a scale of 0 (best possible outcome) to 100 (worst possible outcome).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
Joint Space Narrowing - Left Hand
units on a scaleRituximab + MTX
Baseline8.45 ± 6.039
Week 249.13 ± 6.004
Change at Week 242.19 ± 5.694
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.3132
SecondaryX-Rays: Right Hand Total Score

Right hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and scores ranged from 0 (best possible outcome) to 180 (worst possible outcome).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
X-Rays: Right Hand Total Score
units on a scaleRituximab + MTX
Baseline12.90 ± 9.433
Week 2412.31 ± 7.828
Change at Week 240.50 ± 7.714
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.8597
SecondaryX-Rays: Left Hand Total Score

Left hand total scores as measured by X-rays examining erosion and joint space narrowing. Total score was calculated as the sum of the erosion score and the joint space narrowing score and ranged from 0 (best possible outcome) to 180 (worst possible outcome).

Time frame:
Baseline and Week 24
Reported as:
Mean · units on a scale
X-Rays: Left Hand Total Score
units on a scaleRituximab + MTX
Baseline10.35 ± 7.192
Week 2410.88 ± 6.813
Change at Week 242.19 ± 6.341
Statistical analysis
  • Rituximab + MTX · Student's t-test · p = 0.3617

Adverse events

Collected over From baseline up to 24 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + MTX—2/10 (20%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventRituximab + MTX
Atrial fibrillationCardiac disorders1/10
Device related infectionInfections and infestations1/10
Most frequent other events
Showing 10 of 19
Most frequent other events
EventRituximab + MTX
InfluenzaInfections and infestations3/10
PharyngitisInfections and infestations3/10
Alanine aminotransferase increasedInvestigations2/10
Diabetes mellitusMetabolism and nutrition disorders2/10
HypothyroidismEndocrine disorders1/10
Apical granulomaGastrointestinal disorders1/10
ParonychiaInfections and infestations1/10
Urinary tract infection bacterialInfections and infestations1/10
Back painMusculoskeletal and connective tissue disorders1/10
Neck painMusculoskeletal and connective tissue disorders1/10

Baseline characteristics

Safety population: all participants who received any part of an infusion of study drug.

Age, Continuous
Age, Continuous(years)Rituximab + MTX
Mean52.42 ± 15.681
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + MTX
Female6
Male4
08

Study locations

1 site
  • Università Degli Studi Di Genova - Dimi; Reumatologia
    Genova, Liguria 16132, Italy
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2007 to primary completion in Jul 2010, 32 months.

Results were first posted in Mar 2015, 4 years 7 months after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 32 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2007
First posted
Jul 18, 2007
StartActual
Oct 25, 2007
Primary completionActual
Jul 23, 2010
CompletionActual
Jul 23, 2010
Results first posted
Mar 12, 2015
Last update
Aug 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00502853
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 18, 2007
Start date
Oct 25, 2007
Primary completion
Jul 23, 2010
Completion
Jul 23, 2010
Results posted
Mar 12, 2015
Last update
Aug 16, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Methotrexate

Start the discussion